Ryan Deschner
Stock Analyst at Raymond James
(4.76)
# 113
Out of 5,150 analysts
19
Total ratings
83.33%
Success rate
58.29%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ryan Deschner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Upgrades: Strong Buy | $92 → $143 | $135.49 | +5.54% | 2 | Nov 19, 2025 | |
| TVRD Tvardi Therapeutics | Downgrades: Market Perform | n/a | $4.02 | - | 2 | Oct 14, 2025 | |
| LQDA Liquidia | Maintains: Strong Buy | $33 → $41 | $34.38 | +19.26% | 4 | Aug 13, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Strong Buy | $29 → $27 | $12.92 | +108.98% | 3 | Aug 8, 2025 | |
| ARDX Ardelyx | Maintains: Outperform | $11 → $12 | $6.65 | +80.45% | 2 | Aug 5, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $52 → $50 | $19.86 | +151.76% | 2 | Aug 1, 2025 | |
| VKTX Viking Therapeutics | Maintains: Strong Buy | $125 → $122 | $32.14 | +279.59% | 1 | Jul 24, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Strong Buy | $26 → $28 | $9.04 | +209.73% | 3 | Jan 14, 2025 |
Palvella Therapeutics
Nov 19, 2025
Upgrades: Strong Buy
Price Target: $92 → $143
Current: $135.49
Upside: +5.54%
Tvardi Therapeutics
Oct 14, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $4.02
Upside: -
Liquidia
Aug 13, 2025
Maintains: Strong Buy
Price Target: $33 → $41
Current: $34.38
Upside: +19.26%
Trevi Therapeutics
Aug 8, 2025
Maintains: Strong Buy
Price Target: $29 → $27
Current: $12.92
Upside: +108.98%
Ardelyx
Aug 5, 2025
Maintains: Outperform
Price Target: $11 → $12
Current: $6.65
Upside: +80.45%
Apellis Pharmaceuticals
Aug 1, 2025
Maintains: Outperform
Price Target: $52 → $50
Current: $19.86
Upside: +151.76%
Viking Therapeutics
Jul 24, 2025
Maintains: Strong Buy
Price Target: $125 → $122
Current: $32.14
Upside: +279.59%
ARS Pharmaceuticals
Jan 14, 2025
Maintains: Strong Buy
Price Target: $26 → $28
Current: $9.04
Upside: +209.73%